MA44018A - Dérivés de tétrahydroisoquinoline - Google Patents

Dérivés de tétrahydroisoquinoline

Info

Publication number
MA44018A
MA44018A MA044018A MA44018A MA44018A MA 44018 A MA44018 A MA 44018A MA 044018 A MA044018 A MA 044018A MA 44018 A MA44018 A MA 44018A MA 44018 A MA44018 A MA 44018A
Authority
MA
Morocco
Prior art keywords
tetrahydroisoquinoline derivatives
tetrahydroisoquinoline
derivatives
Prior art date
Application number
MA044018A
Other languages
English (en)
Other versions
MA44018B1 (fr
Inventor
Luke Ashcraft
Scott Emile Collibee
Marc Garard
Takashi Kamikubo
Hiroshi Kiyohara
Pu-Ping Lu
Fady Malik
Yuji Matsushima
Kayoko Mihara
Masanori Miura
Bradley Paul Morgan
Munemichi OHE
Tomoyuki Saito
Ippei Sato
Yasuhiro Shiina
Hiroaki Tanaka
Jeffrey Michael Warrington
Susumu Yamaki
Original Assignee
Astellas Pharma Inc
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Cytokinetics Inc filed Critical Astellas Pharma Inc
Publication of MA44018A publication Critical patent/MA44018A/fr
Publication of MA44018B1 publication Critical patent/MA44018B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA44018A 2016-02-12 2017-02-10 Dérivés de tétrahydroisoquinoline MA44018B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662285039P 2016-02-12 2016-02-12
PCT/US2017/017295 WO2017139526A1 (fr) 2016-02-12 2017-02-10 Dérivés de tétrahydroisoquinoline

Publications (2)

Publication Number Publication Date
MA44018A true MA44018A (fr) 2018-12-19
MA44018B1 MA44018B1 (fr) 2022-05-31

Family

ID=59561239

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44018A MA44018B1 (fr) 2016-02-12 2017-02-10 Dérivés de tétrahydroisoquinoline

Country Status (34)

Country Link
US (5) US9914741B2 (fr)
EP (2) EP3413892B1 (fr)
JP (2) JP6832943B2 (fr)
KR (1) KR20180120701A (fr)
CN (2) CN113666938A (fr)
AR (1) AR107592A1 (fr)
AU (1) AU2017217663B2 (fr)
BR (1) BR112018016475A2 (fr)
CA (1) CA3012839A1 (fr)
CL (1) CL2018002287A1 (fr)
CO (1) CO2018007920A2 (fr)
CY (1) CY1125222T1 (fr)
DK (1) DK3413892T3 (fr)
ES (1) ES2913423T3 (fr)
HR (1) HRP20220655T1 (fr)
HU (1) HUE058820T2 (fr)
IL (1) IL261055B (fr)
LT (1) LT3413892T (fr)
MA (1) MA44018B1 (fr)
MD (1) MD3413892T2 (fr)
MX (1) MX379159B (fr)
NZ (1) NZ746311A (fr)
PH (1) PH12018501694B1 (fr)
PL (1) PL3413892T3 (fr)
PT (1) PT3413892T (fr)
RS (1) RS63240B1 (fr)
RU (1) RU2743424C2 (fr)
SG (1) SG11201806416XA (fr)
SI (1) SI3413892T1 (fr)
SM (1) SMT202200201T1 (fr)
TW (2) TWI773118B (fr)
UA (1) UA124879C2 (fr)
WO (1) WO2017139526A1 (fr)
ZA (1) ZA201804947B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201806416XA (en) 2016-02-12 2018-08-30 Astellas Pharma Inc Tetrahydroisoquinoline derivatives
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
US11981644B2 (en) * 2020-11-06 2024-05-14 Cytokinetics, Inc. Bicyclic 1,4-diazepanones and therapeutic uses thereof
WO2025080100A1 (fr) * 2023-10-11 2025-04-17 한국화학연구원 Nouveau composé di-amide, son procédé de préparation et composition pharmaceutique pour la prévention ou le traitement du cancer ou de maladies auto-immunes le comprenant en tant que principe actif
CN117379425A (zh) * 2023-11-14 2024-01-12 广州日聚商贸发展有限公司 喹啉-4-羧酸在抗衰老产品以及保护肝脏、促进肝脏再生产品制备中的应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3301857A (en) 1963-08-26 1967-01-31 Hoffmann La Roche Spiro
SE368009B (fr) 1971-09-16 1974-06-17 Kabi Ab
BR9710808A (pt) * 1996-08-06 1999-08-17 Pfizer Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos
WO1998013350A1 (fr) 1996-09-25 1998-04-02 Zeneca Limited Derives quinolines inhibant les effets de facteurs de croissance tels que le facteur de croissance endotheliale vasculaire
US6410254B1 (en) 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7202051B1 (en) 1999-05-18 2007-04-10 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US6743599B1 (en) 1999-05-18 2004-06-01 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
JP2001106673A (ja) * 1999-07-26 2001-04-17 Banyu Pharmaceut Co Ltd ビアリールウレア誘導体
CA2380389A1 (fr) * 1999-07-26 2001-02-01 Banyu Pharmaceutical Co., Ltd. Derives de biaryluree
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
KR20070015598A (ko) * 2004-04-28 2007-02-05 다케다 야쿠힌 고교 가부시키가이샤 융합 퀴놀린 유도체 및 이의 용도
AU2006331765A1 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones and use thereof as kinase inhibitor
GB0613208D0 (en) 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
PL2069352T3 (pl) * 2006-08-02 2014-03-31 Cytokinetics Inc Określone cząstki chemiczne, kompozycje i sposoby
NZ577980A (en) * 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
MY162052A (en) 2007-01-05 2017-05-31 Daiichi Sankyo Co Ltd Fused substitute aminopyrrolidine derivative
CL2008001500A1 (es) 2007-05-25 2008-12-26 Amgen Inc Compuestos derivados de hidroxietil amina sustituidas, moduladores de betasecretasa; proceso de preparacion de dichos c ompuestos; composicion farmaceutica que los comprende; y su uso para tratar un trastorno neurologico, tal como alzheimer, sindrome de down, demencia degenerativa, entre otros.
JP5451646B2 (ja) * 2008-02-27 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
CN101518971B (zh) * 2008-02-29 2012-07-18 E.I.内穆尔杜邦公司 聚酯叠层膜和使用该叠层膜的太阳能电池板
NZ592008A (en) * 2008-10-02 2011-12-22 Taisho Pharmaceutical Co Ltd 7-piperidinoalkyl-3,4-dihydroquinolone derivative
JP5444365B2 (ja) 2008-10-29 2014-03-19 デシフェラ ファーマシューティカルズ，エルエルシー 抗癌活性および抗増殖活性を示すシクロプロパンアミドおよび類似物質
WO2010131145A1 (fr) 2009-05-12 2010-11-18 Pfizer Limited Dérivés de cyclobutène-dione
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
WO2011159760A1 (fr) 2010-06-16 2011-12-22 Vitae Pharmaceuticals, Inc. Hétérocycles à 5, 6 et 7 chaînons substitués, médicaments contenant ces composés et leur utilisation
CA2827724A1 (fr) * 2011-02-18 2012-08-23 Allergan, Inc. Derives de 6,7-dialkoxy-3-isoquinolinol substitues en tant qu'inhibiteurs de la phosphodiesterase 10 (pde10a)
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
HUP1100241A3 (en) 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
KR20160046693A (ko) 2012-04-02 2016-04-29 싸이토키네틱스, 인코포레이티드 횡격막 기능을 향상시키는 방법들
CA2869675C (fr) 2012-04-11 2022-06-14 Cytokinetics, Inc. Procedes d'amelioration de la resistance a la fatigue des muscles du squelette
AR091699A1 (es) * 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
SI3137622T1 (sl) 2014-04-29 2022-05-31 Cytokinetics, Inc. Postopki za zmanjšanje upada vitalne kapacitete
JP6573618B2 (ja) 2014-09-09 2019-09-11 アステラス製薬株式会社 尿失禁予防用及び／又は治療用新規医薬組成物
SG11201806416XA (en) 2016-02-12 2018-08-30 Astellas Pharma Inc Tetrahydroisoquinoline derivatives

Also Published As

Publication number Publication date
UA124879C2 (uk) 2021-12-08
LT3413892T (lt) 2022-06-10
BR112018016475A2 (en) 2018-12-26
AR107592A1 (es) 2018-05-16
PH12018501694B1 (en) 2023-08-30
SMT202200201T1 (it) 2022-07-21
CN109069498A (zh) 2018-12-21
HUE058820T2 (hu) 2022-09-28
HRP20220655T1 (hr) 2022-06-24
EP3413892A1 (fr) 2018-12-19
EP3413892A4 (fr) 2019-08-14
JP6832943B2 (ja) 2021-02-24
IL261055A (en) 2018-10-31
CO2018007920A2 (es) 2018-12-14
RU2018130002A (ru) 2020-03-12
RU2743424C2 (ru) 2021-02-18
WO2017139526A8 (fr) 2018-08-16
CL2018002287A1 (es) 2019-01-04
US20190194220A1 (en) 2019-06-27
JP7137650B2 (ja) 2022-09-14
TW202138373A (zh) 2021-10-16
US20170233402A1 (en) 2017-08-17
US9914741B2 (en) 2018-03-13
ES2913423T3 (es) 2022-06-02
EP4032877A1 (fr) 2022-07-27
TWI773118B (zh) 2022-08-01
SI3413892T1 (sl) 2022-06-30
CN109069498B (zh) 2021-08-17
US10689393B2 (en) 2020-06-23
PH12018501694A1 (en) 2019-01-28
NZ746311A (en) 2022-08-26
US11479561B2 (en) 2022-10-25
ZA201804947B (en) 2024-05-30
KR20180120701A (ko) 2018-11-06
US20180148458A1 (en) 2018-05-31
TW201741316A (zh) 2017-12-01
PL3413892T3 (pl) 2022-06-13
US20200270266A1 (en) 2020-08-27
TWI719138B (zh) 2021-02-21
EP3413892B1 (fr) 2022-04-20
JP2021073270A (ja) 2021-05-13
AU2017217663A1 (en) 2018-10-04
MA44018B1 (fr) 2022-05-31
MD3413892T2 (ro) 2022-06-30
RS63240B1 (sr) 2022-06-30
MX379159B (es) 2025-03-10
RU2018130002A3 (fr) 2020-03-24
SG11201806416XA (en) 2018-08-30
PT3413892T (pt) 2022-05-30
MX2018009759A (es) 2018-11-29
CY1125222T1 (el) 2025-03-28
US20230125280A1 (en) 2023-04-27
WO2017139526A1 (fr) 2017-08-17
JP2019509267A (ja) 2019-04-04
CN113666938A (zh) 2021-11-19
DK3413892T3 (da) 2022-05-23
AU2017217663B2 (en) 2021-06-17
US10259821B2 (en) 2019-04-16
IL261055B (en) 2021-03-25
CA3012839A1 (fr) 2017-08-17

Similar Documents

Publication Publication Date Title
DK3319956T3 (da) Substituerede oxopyridinderivater
EP3280487A4 (fr) Estimation de distance électrode-nerf
DK3642202T3 (da) Dihydro-pyrrolo-pyridin-derivater
MA41898A (fr) Dérivés de quinazolinone bicyclique
DK3204359T3 (da) Tetrahydroisoquinolinderivater
EP3457851A4 (fr) Dérivés de sobétirome
LT3402792T (lt) Chinolin-2-ono dariniai
PT4039675T (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EP3455077C0 (fr) Impression
EP3546462A4 (fr) Nouveau dérivé d'oxoisoquinoline
EP3449930C0 (fr) Agent de formation de synapses
DE112017003628A5 (de) Fortbewegungshilfe
SMT202200173T1 (it) Composti
MA41790A (fr) Dérivé de morphinane
EP3430073A4 (fr) Composition de polyaryléthercétone
LT3371168T (lt) Indolin-2-ono dariniai
EP3309163A4 (fr) Dérivé de dihydropyrrolopyrazole substitué
EP3554637A4 (fr) Dérivés de spiropipéridine
DK3551355T3 (da) Immobiliseret indsats
EP3371163A4 (fr) Dérivés de pyrrolidine
EP3413892A4 (fr) Dérivés de tétrahydroisoquinoline
HUE059063T2 (hu) Tumorellenes hatású vegyületek
EP3444345C0 (fr) Dérivé d'arnmicro-143
EP3400220A4 (fr) Dérivés de pyrazole
MA49708A (fr) Dérivés de dihétérocycle liés à cycloalkyle